Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Takashi WadaTatsuo HosoyaDaisuke HondaRyusuke SakamotoKazutaka NaritaTomomitsu SasakiDaisuke OkuiKenjiro KimuraPublished in: Clinical and experimental nephrology (2018)
These findings support that diabetic nephropathy combined with hyperuricemia may be associated with kidney dysfunctions. Topiroxostat provides strict control of the serum uric acid level preventing decline of eGFR in these patients.
Keyphrases
- uric acid
- diabetic nephropathy
- metabolic syndrome
- placebo controlled
- double blind
- end stage renal disease
- small cell lung cancer
- ejection fraction
- clinical trial
- chronic kidney disease
- prognostic factors
- epidermal growth factor receptor
- randomized controlled trial
- squamous cell carcinoma
- tyrosine kinase
- rectal cancer